Huntleigh Technology's profits up 36% in first half of 1995:
This article was originally published in Clinica
In the six months to June 30th, 1995, Huntleigh Technology (UK) reported pre-tax profits of £7.17 million ($11.5 million), up 36% on 1994's first half. Turnover rose 34% to £47.5 million. Chairman Rolf Schild expects "another record year" in 1995 and that new product launches will contribute to growth next year. The HNE Diagnostics division is in the process of launching new products, including Rheo Dopplex, a hand-held multifunctional device combining the Dopplex technology with digital photoplethysmography, for use in primary care and vascular assessment.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.